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Abstract
Background: This trial aims to evaluate the effectiveness of a group cognitive behavioural intervention to alleviate
menopausal symptoms (hot flushes and night sweats) in women who have had breast cancer treatment. Hot
flushes and night sweats are highly prevalent but challenging to treat in this population. Cognitive behaviour
therapy has been found to reduce these symptoms in well women and results of an exploratory trial suggest that
it might be effective for breast cancer patients. Two hypotheses are tested:
Compared to usual care, group cognitive behavioural therapy will:
1. Significantly reduce the problem rating and frequency of hot flushes and nights sweats after six weeks of
treatment and at six months post-randomisation.
2. Improve mood and quality of life after six weeks of treatment and at six months post-randomisation.
Methods/Design: Ninety-six women who have completed their main treatment for breast cancer and who have
been experiencing problematic hot flushes and night sweats for over two months are recruited into the trial from
oncology and breast clinics in South East London. They are randomised to either six weekly group cognitive
behavioural therapy (Group CBT) sessions or to usual care. Group CBT includes information and discussion about
hot flushes and night sweats in the context of breast cancer, monitoring and modifying precipitants, relaxation and
paced respiration, stress management, cognitive therapy for unhelpful thoughts and beliefs, managing sleep and
night sweats and maintaining changes.
Prior to randomisation women attend a clinical interview, undergo 24-hour sternal skin conductance monitoring,
and complete questionnaire measures of hot flushes and night sweats, mood, quality of life, hot flush beliefs and
behaviours, optimism and somatic amplification. Post-treatment measures (sternal skin conductance and
questionnaires) are collected six to eight weeks later and follow-up measures (questionnaires and a use of medical
services measure) at six months post-randomisation.
Discussion: MENOS 1 is the first randomised controlled trial of cognitive behavioural therapy for hot flushes and
night sweats that measures both self-reported and physiologically indexed symptoms. The results will inform future
clinical practice by developing an evidence-based, non-medical treatment, which can be delivered by trained
health professionals.
Trial Registration: Current Controlled Trials ISRCTN13771934
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Hot flushes and night sweats (HF/NS) affect 65-85% of
breast cancer survivors, with 60% rating them as severe
[1]. They are associated with sleep problems, reduced
health-related quality of life [2-4] and are more chronic
in this population [5]. Chemotherapy and endocrine
treatments such as tamoxifen can induce or exacerbate
menopausal symptoms and those taking hormone ther-
apy (HT) are generally advised to stop treatment. HT is
an effective treatment, but there is uncertainty asso-
ciated with its safety. Results of prospective trials [6,7]
highlight the association between HT and breast cancer
and cardiovascular risks. Therefore a clear need exists
for safe and effective non-hormonal targeted therapies
that are well tolerated [8].
The exact aetiology of HF/NS is unknown, but they
appear to be associated with the rate of change of
plasma oestrogen, which influences the thermoregula-
tory system via the hypothalamus [9]. Alterations in oes-
trogen levels and neurotransmitters (norepinephrine and
serotonin) have been implicated in the pathogenesis of
HF/NS [5]. Freedman [10] proposed that there is a nar-
rowed thermoneutral zone (temperature range in which
thermoregulation is not triggered) in women who have
HF/NS resulting in flushes being triggered by small ele-
vations in core body temperature, caused by changes in
ambient temperature or triggers, such as anxiety or sti-
mulants. There is some evidence that the thermoneutral
zone is narrowed by elevated brain norepinephrine
[10,11], and that stressors increase incidence of hot
flushes [12]. Anxiety [13] and cognitions (negative
thoughts associated with embarrassment, social anxiety,
feeling out of control and unable to cope) are associated
with reports of more frequent and problematic HF/NS
[14,15], and lifestyle, mood and cognitive and beha-
vioural reactions are likely to influence perception of
symptoms [16]. Although the aetiology of hot flushes
and night sweats is likely to be the same, their impacts
on women are very different. Hot flushes during the day
tend to be associated with problems of social anxiety,
discomfort and managing day to day activities, whereas
night sweats occurring during the night tend to be asso-
ciated with sleep disruption and associated problems.
Evaluating treatment efficacy depends on valid and
reliable measures of HF/NS. The most commonly used
measures of HF/NS are women’so w ns e l f - r e p o r t s .
These include diaries, in which women note the time
when a hot flush occurs and usually a severity rating
(e.g. mild, moderate or severe). Electronic event markers
can also provide a convenient method of registering a
perceived hot flush. Sternal skin conductance (SSC) is
considered to be the most valid physiological index of
HF/NS [17]. A hot flush is marked by a sudden increase
in skin conductivity, due to a sweat response, which
tails off as sweating decreases (a ‘swishy tail’). This pat-
tern is in contrast with a ‘saw-tooth’ fluctuation in
sweating which occurs in typical thermoregulatory con-
trol. SSC does not, however, correlate well with subjec-
tive measures of severity or problem ratings, and hot
flushes defined by SSC and self-reported hot flushes are
not always concordant [18]. Reasons for discordance are
not well understood, but use of both measures can
increase understanding of the impacts of interventions
[16]. For example, self-report but not physiological mea-
sures (SSC) have shown placebo effects [19], but physio-
logical measures are less predictive of problem ratings
and help seeking than self-reports. For these reasons
SSC should be used together with self-report measures
(frequency and the extent to which they are proble-
matic) [20]. SSC has not yet been used to evaluate treat-
ments in the UK. 24 hour SSC monitoring has been
piloted and has been acceptable to women [21,22].
Non-hormonal treatments for menopausal symptoms in
breast cancer patients
Non-hormonal treatments for HF/NS tend to be pre-
ferred but the efficacy and acceptability of treatments
limit their use. Following a systematic review of non-
hormonal medicines for HF/NS, Nelson, Vesco, Haney
and others [23] concluded that SSRIs or SNRIs, cloni-
dine and gabapentin trials provide evidence for efficacy
but that adverse effects might restrict use for some
women. Carpenter, Storniolo, Johns et al [19] reported
modest reductions (22%) in HF/NS with Venlafaxine
(37.5 mgs) but most patients discontinued treatment at
12 months follow up. These conclusions support those
of a position statement by the North American Meno-
pause Society [24]. Furthermore, possible negative
interactions between some SSRIs and the effects of
tamoxifen may limit prescribing options for women who
have had breast cancer [25].
Non-medical treatments are popular, including acu-
puncture, yoga, exercise, and cognitive behavioural
therapy. Studies of acupuncture often report significant
reductions in HF/NS following treatment, although few
studies report between group effects when compared
to sham, superficial or placebo acupuncture [26].
A recent meta-analysis [27] of 4 RCTs of acupuncture
for HF/NS in women who have had breast cancer found
one RCT that reported significantly fewer HF/NS fol-
lowing acupuncture compared to sham acupuncture
[28]. In well women one study out of six reviewed [29]
reported a reduction in severity following acupuncture
compared to placebo [30]. Both studies involved a
comparatively large number of acupuncture sessions,
suggesting that it may be effective over and above pla-
cebo effects if delivered intensively. Furthermore it
would also be worth investigating the reasons for these
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enduring.
Regular exercise has been associated with fewer HF/NS
in cross-sectional studies, but interventions to reduce
symptoms using exercise have been less successful [31]. In
a systematic review of seven studies, about half reported
significant within-group improvements following exercise,
but only two reported improvements in HF/NS compared
to a no treatment control (one was not powered to find a
significant difference [32]). Although there were no studies
focusing on breast cancer patients, an RCT of exercise for
breast cancer patients with treatment induced HF/NS is
due to publish findings in 2011 [33]. Theoretically, yoga
may be more effective than exercise; as well as being low
intensity exercise, yoga is used as a relaxation technique,
which may also reduce HF/NS [34]. A systematic review
revealed a reduction in reported HF/NS in 4 out of 7 stu-
dies [35], however most RCTs did not find an effect. The
exception was an RCT of an intensive yoga programme
(60 minutes a day, 5 days a week for 8 weeks) [36]. The
only study to measure frequency of physiological HF/NS
as well as self-reported HF/NS found no reduction in ster-
nal skin conductance or diary reported hot flushes and
night sweats following yoga [37]. There is growing evi-
dence that relaxation therapy and paced respiration can
alleviate HF/NS in well women [38-41]. In two preliminary
studies with breast cancer patients relaxation significantly
reduced HF/NS after 12 sessions [42] but not after one
session [43]. A treatment package including behavioural
(relaxation and counselling) and pharmacological inter-
ventions for breast cancer patients has been evaluated in
the US with positive results [44].
A CBT intervention for HF/NS, which includes relaxa-
tion and paced respiration, has been developed in the
UK by Hunter and colleagues [45-47]. This four-session
CBT intervention was shown to be effective in an
exploratory patient preference trial of well women
(around 40% reduction of HF frequency and problem
rating) [45]; a finding replicated by Keefer and Blan-
chard [48] using 8 sessions of CBT. Women who have
had breast cancer tend to experience more frequent and
problematic menopausal symptoms than well women
going through the natural menopause [3]. In a study of
113 women, who had completed active treatment for
breast cancer within the past 5 years, 80% reported HF
and 72% NS, a significantly higher prevalence than
found in well postmenopausal women [49]. Treatment
preferences were explored and preferences were
expressed for CBT (63%), complementary therapies
(46%), antidepressant treatment (25%) and HT (26%).
53% expressed interest in group and/or individual CBT
sessions [3].
Based on earlier work, an exploratory trial of a six-
session Group CBT intervention was evaluated in a
pre-post study of 24 breast cancer patients [47]. The
weekly problem rating reduced on average from 5.9
(SD = 2.1) to 3.4 (SD = 1.8) at post-treatment and 2.8
(SD = 1.8) at follow-up (10 point scale); frequency of
HF/NS per week reduced from 68.2 (SD = 28.7) to 46.7
(SD = 30.2) at post-treatment and to 36.9 (SD = 32.5) at
3 months follow up; a significant reduction in HF pro-
blem rating and frequency. Feedback from the women,
elicited during and at the end of the groups, was very
positive [47]. Relaxation/breathing and cognitive strate-
gies used at the onset of HF/NS, as well as group sup-
port to make behavioural changes, were seen as most
useful. The majority (88%) completed the 3 month fol-
low-up assessment, suggesting good adherence to the
study. These results suggest that CBT may be effective
in reducing HF/NS and their impacts in breast cancer
patients. However, a randomised controlled trial is
needed. Furthermore, most studies of the efficacy of
CBT used self-reported improvements in HF/NS, thus
investigation into the impacts on physiological symp-
toms is warranted.
Current study
This present study aims to evaluate the effectiveness of
Group CBT to alleviate HF/NS in women who have had
treatment for breast cancer, comparing Group CBT and
usual care in a randomised controlled trial, with both
physiological and self-reported measures of HF/NS and
a 6-month post-randomisation follow-up. We hypothe-
size that Group CBT will be more effective than usual
care in reducing HF/NS problem rating and frequency.
Secondary analyses will examine the effects of Group
CBT on hypothesised mediating variables, including
mood, quality of life, beliefs and behaviours, optimism
and somatisation. If effective, the treatment can be pro-
moted by publication of the treatment manual and by
training and supervising health professionals in the
application of the treatment.
The trial tests four main hypotheses:
1. There will be a significant reduction in problem rating
of HF/NS following Group CBT compared to usual care.
2. There will be a significant reduction in frequency of
self-reported and SSC-defined HF/NS following Group
CBT compared to usual care.
3. Changes in problem rating and frequency of HF/NS
following Group CBT will be maintained at six months
post-randomisation.
4. There will be significant improvements in mood,
beliefs and behaviours about HF/NS and quality of life
following Group CBT compared to usual care.
Methods/Design
The study design is shown in Figure 1. It is a randomised
controlled trial of Group CBT for HF/NS in women who
have completed treatment for breast cancer. Participants
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to clinic support) or to usual care plus six weekly sessions
of Group CBT (herein referred to as Group CBT). The
Group CBT was developed from previous work and an
exploratory trial [45,50] and is specified in a treatment
manual. Group CBT is delivered by a clinical psychologist
in this trial, but the treatment is designed to be facilitated
by appropriately trained and supervised health profes-
sionals. Post-treatment assessment is conducted 7-
9 weeks post-randomisation (0-2 weeks after 6 weeks of
treatment or usual care). Follow up assessment is con-
ducted 6 months post-randomisation. The primary
outcome is problem rating of HF/NS at post-treatment
assessment. The trial is conducted in compliance with
the Helsinki Declaration [51] and is badged with the
National Cancer Research Network (UKCRN; Study ID:
4975). NHS REC approval has been granted (South East
London 2 REC, ref: 08/H0802/106) and local ethics and
R&D approval has been obtained for recruitment of
breast cancer patients from all hospitals in the South
East London Cancer Research Network (SELCRN).
The trial is registered with Current Controlled
Trials (ISRCTN13771934). A trial steering committee
(TSC) has agreed the research protocol and monitors
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Baseline assessment 
Complete informed consent process, pre-treatment 
questionnaires & 24-hour hot flush monitoring 
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USUAL CARE + GROUP CBT  
Post-treatment assessment 
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24-hour hot flush monitoring  
6 month follow up assessment 
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USUAL CARE 
Post-treatment assessment 
Questionnaires, use of medical services, 
24-hour hot flush monitoring  
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Questionnaires, use of medical services 
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Informed of study in clinic by 
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Screened for eligibility & patient 
information sheet 
Complete two-week hot flush diary 
Figure 1 Description of overall trial design.
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tored by a data management committee (DMC).
Study sample and recruitment
Participants are recruited from six hospital sites in
South East London over an 18 month period from
March 2009 to September 2010. Breast cancer patients
who report HF/NS at clinic appointments are being
recruited into the study by referrals from oncologists,
surgeons, radiographers, breast care nurses and SELCRN
research nurses working in clinics. Participants are also
a b l et oo p ti nt ot h es t u d yb yr e s p o n d i n gt op o s t e r s ,
leaflets and websites. Inclusion criteria
1. English speaking patients, aged 18 plus, who have
had breast cancer or ducal carcinoma in situ.
2. No evidence of distant metastatic disease.
3. Have had problematic HF/NS for at least 2
months.
4. Have completed active treatment (surgery, radio-
therapy and/or chemotherapy) and being in remis-
sion, but may be on endocrine treatment such as
tamoxifen.
5. Prior medical treatment for HF/NS is recorded. If
women have derived partial benefit and are stable on
a treatment, they can be included if they have been
on this treatment for 2 months or longer.
Women are excluded if depression or general cancer
concerns are the main problem that they are seeking
help for, not HF/NS, or if they are unable to commit
time to attend the sessions.
Procedure
Women referred from the clinics are contacted by tele-
phone for a screening interview. A researcher conducts
an eligibility check using the above criteria and explains
what happens in the two arms of the trial and the ran-
domisation process. Those eligible and interested in par-
ticipating are sent a participant information sheet, a
socio-demographic questionnaire and a two-week HF/
NS diary to complete, and an appointment for the base-
line assessment is arranged. The consent process is
completed whereby the researcher summarises the infor-
mation in the participant information sheet and
responds to questions about the study. Participants then
provide written consent. Diaries and demographic ques-
tions are not collected from those who do not consent
or who withdraw consent during baseline assessment.
The researcher then conducts a clinical interview cover-
ing breast cancer treatment history, medical history
including mental health issues, menopause symptoms
and treatments used, concomitant medication and ther-
apy use, and current life concerns. Participants are given
a questionnaire to complete, assessing HF/NS frequency
and problem rating, beliefs about HF/NS, health related
quality of life, stress, dispositional optimism and somati-
sation. After checking that the participant has no allergy
to adhesive dressings (e.g. plasters) and does not wear a
pacemaker, the SSC hot flush monitor is fitted. Partici-
pants are given a magnet event marker, worn on a bra-
celet, and a 24-hour hot flush diary. They mark the
experience of a HF/NS by passing the magnet over the
monitor and noting the time and severity of the HF/NS
in the diary. Participants wear the monitor for 24 hours,
carrying out their usual daily activities and removing the
monitor only to shower or bathe.
Randomisation
Women are randomised in blocks of 12-20, when suffi-
cient participants have been assessed at baseline. Partici-
pant IDs are sent for randomisation by an independent
statistician at the Mental Health and Neurology Clinical
Trials Unit at King’s College London. Women are strati-
fied by age (<50, > = 50) and individually randomised to
the two treatment arms in the ratio 1:1, using an inter-
net-based system. Group allocation is sent to the clinical
psychologist who delivers the treatment (and therefore
cannot be blind to condition). The trial coordinator and
trial statistician are not informed of group allocation.
Within four weeks after randomisation, women in the
group treatment arm attend six 1 1/2 hour sessions of
g r o u pC B T ,o n c eaw e e kf o rs i xw e e k s .W o m e nf r o m
both arms attend post-treatment assessments in the two
weeks following the treatment phase (see Figure 1).
Post-treatment assessments are conducted by the trial
coordinator, who is blind to group allocation. Partici-
pants are interviewed about their use of health services
and treatments, as well as any changes to lifestyle and
health during the treatment phase. They complete post-
treatment questionnaires measuring HF/NS frequency
and severity, HF/NS beliefs, health related quality of life,
stress and somatisation, and repeat the 24-hour SSC hot
flush monitoring. Six months after randomisation, parti-
cipants complete a follow-up questionnaire identical to
the post-treatment questionnaire, including use of health
services and treatments, and changes in lifestyle and
health over the previous four months since post-treat-
ment assessment.
Group CBT Intervention
Group CBT comprises 6 weekly sessions of 1.5 hours each.
The approach is interactive and psycho-educational,
with a focus on helping participants to develop indivi-
dual treatment strategies through active cognitive and
behavioural change. Each session is run according to
protocol set out in a treatment manual, including pre-
sentation slides and handouts. A clinical psychologist
has been trained to deliver the treatment and assistants
also are trained to assist in the groups. Sessions are
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cognitive behavioural therapy, rate 10% of the sessions
for adherence to protocol using a coding sheet created
for the purpose. The components of each session are
listed in Table 1. The change techniques used in each
component are categorised using a 40-item revised ver-
sion of Abraham and Michie’s 26-item taxonomy of
behaviour change techniques [52,53]. At each session
participants create an action plan of homework to carry
out between sessions. At the start of each session parti-
cipants feed back their experiences of implementing
changes during the previous week. Where difficulties are
encountered, the group is encouraged to provide sup-
port and help the participant in problem-solving. Posi-
tive effects of changes are highlighted and discussed.
Participants continue to practice, monitor and imple-
ment changes from previous weeks in addition to the
new action plan each week. Paced breathing and relaxa-
tion are practiced within each session and as homework
using a CD (developed for the treatment).
Session 1 aims to engage participants by introducing
them to the CBT model of HF/NS [16,46]. Participants
discuss their experiences of menopause and personal
goals for the treatment. They are informed about, and
discuss, physiological, cognitive, behavioural, and emo-
tional components of HF/NS. This is embedded within
an overall CBT model of menopausal symptoms that
acknowledges the effect of stress upon the hot flush
threshold. Common triggers are discussed and for
homework participants monitor HF/NS for triggers
and experiment by modifying them. Full body relaxa-
tion is introduced in the first session without paced
breathing, and participants practice relaxation for
homework.
Session 2 reviews homework and introduces a cogni-
tive behavioural model of stress and stress management
using a series of interactive exercises and discussion.
Cognitive therapy is used to increase awareness of the
role of unhelpful and overly negative thoughts and to
facilitate calm responses. Behavioural strategies are
encouraged to promote well-being and to reduce stress.
Participants are asked to identify a stress reducing goal
and implement it as homework. Paced breathing (slow,
deep and even breathing with attentional focus on the
breathing) is introduced to the relaxation session and
participants are prompted to continue practice of paced
breathing and relaxation as homework.
Session 3 focuses on cognitive and behavioural aspects
of hot flushes. Participants revisit the CBT model intro-
duced in session 1 and information about psychological
processes contributing to distress during a hot flush are
introduced. Cognitive behavioural strategies for mana-
ging hot flushes during social situations, and in relation
to a perceived loss of control are discussed. Participants
create an action plan to implement a cognitive beha-
vioural strategy as homework. The role of paced breath-
ing in reducing the impact of a hot flush is introduced
and participants are asked to practice paced breathing at
the onset of a flush for homework. This is suggested
within an approach of accepting the flush (not fighting
it), and letting the flush flow over them as they breathe;
in doing so the focus of attention is on the body and
breathing rather than thoughts. They then redirect
attention to their activities.
Session 4 is the first of two sleep sessions, and lays the
foundations for managing night sweats by improving gen-
eral sleep quality. Participants are taught the mechanisms
of sleep and cognitive processes that influence subjective
judgements of sleep to address anxieties about sleep.
Behavioural strategies (adapted from Harvey [54]) are
introduced and participants are asked to create a sleep
goal (action plan) and implement it as homework.
Session 5 builds on behavioural sleep strategies by
adding in the cognitive component. Participants discuss
cognitive strategies to address sleep-related and general
anxieties leading to wakefulness. Calm management of
n i g h ts w e a t si se n c o u r a g e dt h a ti n c o r p o r a t e sp a c e d
breathing. Strategies to deal with overly anxious think-
ing are discussed. Participants are asked to identify and
implement a relevant sleep goal as homework.
Session 6 reviews the overall model and goals of the
previous five weeks. Participants write and share indivi-
dual maintenance plans by considering cognitive and
behavioural changes made through psycho-education and
homework tasks. They make action plans to maintain
changes and identify potential barriers or setbacks and
ways of overcoming them. This session also schedules
some time for discussion of menopause-related topics not
covered in previous sessions, chosen by the participants,
which may include weight gain, memory, adjusting to life
after breast cancer, and sexuality.
Usual care
The control arm receives standard care, that is, they have
access to their oncologist and clinical nurse specialist, as
well as cancer information and support services. Treat-
ments and services accessed during the treatment phase
are logged at post-treatment assessment. The usual care
group are offered a form of CBT off-trial at the end of the
trial.
Measures
The measures taken at each stage of the trial are sum-
marised in table 2.
Socio-demographics
Socio-demographic variables include date of birth,
height, weight, ethnicity, number of children, education,
marital status, employment s t a t u s ,s m o k i n g ,d r i n k i n g
and exercise. Breast cancer treatment, use of treatments
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Intervention Component Change Technique
SESSION 1
▪ Participants discuss experiences of breast cancer, HF/NS, and personal goals for treatment 28, 6
▪ Provide information about physiology of HF/NS and the role of thoughts, feelings and behaviours 1
▪ Discuss triggers of HF/NS and ways to modify them 28, 8
▪ Introduction to full body relaxation 21, 26
HOMEWORK:
▪ Monitor and modify triggers of HF/NS 16, 17
▪ Practice full body relaxation 9, 26
SESSION 2
▪ Participants feedback on homework from previous session, with group support and problem solving of difficulties
and focus on positives
19, 28, 29, 8, 18
▪ Provide information on stress and discuss its impacts on HF/NS 36, 1, 2
▪ Provide examples of cognitive and behavioural stress management techniques 36, 21
▪ Participants create a specific stress goal to enhance wellbeing 7
▪ Introduce paced breathing to relaxation 21, 26
HOMEWORK as before plus:
▪ Implement stress goal 7
▪ Practice paced breathing 9, 26
SESSION 3
▪ Participants feed back on homework from previous sessions, as above 19, 28, 29, 8, 18
▪ Discuss cognitive, emotional and behavioural reactions to HF/NS and generate more helpful responses 8
▪ Participants try out some cognitive and behavioural strategies for managing HF/NS 26
▪ Introduce use of paced breathing and cognitive strategies at onset of HF/NS to reduce impact of flush 21, 26
HOMEWORK as before plus:
▪ Monitor thoughts, feelings and behavioural reactions to HF/NS, practice more helpful reactions 17, 26
▪ Practice paced breathing at the onset of a HF/NS 9, 26
▪ Complete a sleep diary for a week 17
SESSION 4
▪ Participants feedback on homework from previous sessions as above 19, 28, 29, 8, 18
▪ Provide information on sleep and discuss sleep diaries 1, 2
▪ Discuss behavioural strategies for improving sleep quality 21
▪ Participants create an action plan to implement two sleep goals 7
▪ Practice relaxation and paced breathing 21, 26
HOMEWORK as before plus:
▪ Implement sleep goals 24
SESSION 5
▪ Participants feedback on homework from previous session as above 19, 28, 29, 8, 18
▪ Provide information on thoughts and sleep 1
▪ Provide tips on managing cognitive and emotional reactions to sleep difficulties 21
▪ Create action plan to change thinking and behaviour when having sleep difficulties 7
▪ Practice Relaxation and Paced breathing 21, 26
HOMEWORK as before plus:
▪ Implement second set of sleep goals 7
SESSION 6
▪ Participants feedback on homework from previous sessions as above 19, 28, 29, 8, 18
▪ Discuss overall progress and write a therapy blueprint by identifying helpful strategies, potential barriers or setbacks,
ways of spotting setbacks and overcoming them, and a maintenance plan for future goals relating to the treatment
35, 16, 17
▪ Group discussion of managing uncertainty and future plans, and symptoms in the context of breast cancer 29, 28
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pies are also recorded.
Primary Outcome: Hot flush problem rating
Hot flush problem rating is a subscale of the Hot Flush
Rating Scale [55], calculated as the mean of three items
each measured on a 10 point scale (low to high), e.g.
“To what extent do you regard your flushes/sweats as a
problem?” (1 = not at all a problem, 10 = very much a
problem).
Secondary Outcomes
Hot flush frequency and severity are assessed using the
following measures:
Hot Flush Rating Scale [55]: Frequency subscale The
frequency subscale of the HFRS is a retrospective
estimation of the number of HF/NS experienced in the
previous week, e.g. “How often have you had hot flushes
in the past week?” Average severity of HF/NS over the
previous week is estimated for hot flushes and for night
sweats separately (1 = mild, 2 = moderate and 3 =
severe).
24-hour hot flush diary Women monitor their HF/NS
prospectively for 24 hours. When they experience a hot
flush or night sweat they note down the severity (1 =
mild, 2 = moderate and 3 = severe) and the time at
which it occurred.
24-hour ambulatory sternal skin conductance and
event marker During the 24-hour diary monitoring per-
iod women wear an ambulatory SSC monitor [56]. The
Table 1 Intervention techniques used in the Group CBT treatment (Continued)
▪ Practice Relaxation and Paced breathing 21, 26
▪ Goodbye and how to access help in the future 29
Notes:
1: Provide information on consequences of behaviour in general*; 2: Provide information on the consequences of behaviour to the individual*; 6: Goal setting
(outcome); 7: Action planning; 8: Barrier identification/Problem solving; 9: Set graded tasks; 16: Prompt self-monitoring of behaviour; 17: Prompt self-monitoring
of outcome; 18: Prompting focus of past success; 19: Provide feedback on performance**; 21: Provide instruction on how to perform a behaviour; 24:
Environmental restructuring; 26: Prompt practice; 28: Facilitate social comparison; 29; Plan social support; 35: Relapse prevention/Coping planning; 36: Stress
Management.
*The definition is interpreted broadly to include consequences of cognition and emotion. According to cognitive behaviour theory there are cognitive and
emotional consequences and antecedents of behaviour which impact upon health outcomes (in this case HF/NS).
**The term performance may be slightly misleading as it suggests that feedback should be judgemental (good or bad), although it is not specifically defined this
way in the taxonomy.
The definitions of change techniques are available on request from Stephanie Ashford (s.ashford@coventry.ac.uk).
Table 2 Study measures
Phase Pre-
baseline
A0 Baseline
assessment
Treatment
phase
A1 Post-
treatment
assessment
A2 Follow up
assessment
Interview measures
Medical history incl. breast cancer treatment, menopause
symptoms, concomitant medications and therapies
X
Questionnaire measures
Weekly diaries X
1 X
2
Demographics: Age, BMI, ethnicity, parity, marital status,
education, employment, smoking, drinking, exercise
X
Hot flush rating scale X X
2 XX
Hot flush beliefs scale X X X
Women’s health questionnaire X X X
Perceived Stress Scale X X X
Somatic Amplification Scale X X X
SF-36 X X X
Life Orientation Test X
Use of services XX
CBT session evaluation X
3
24 hour monitoring
Sternal skin conductance X X
24 hour diary X X
Notes:
1Two weekly diaries completed prior to baseline assessment.
2Completed each week for 6 weeks by those randomised to Group CBT only.
3Completed by participants receiving Group CBT only.
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Page 8 of 12monitor is approximately 6 × 6 cm, with two 8 cm elec-
trodes attached to an adhesive electrode patch by press
studs. The adhesive electrode patch is attached to the
sternum, two inches below the sternal notch, which
holds the monitor close to the body. Skin conductance
is measured by passing a pulse through the electrodes
every 5 seconds, indicated by a green flash of an LED
on the monitor. A hot flush is defined by an increase in
conductance of 2 mmhos or more in 30 seconds, occur-
ring no less than 15 minutes since the last SSC-defined
HF/NS (i.e. 15 minute lock out period [57]). For each
SSC-defined hot flush or night sweat, SSC level and the
time at which it occurred are extracted for analysis.
Women can indicate that they are experiencing a HF/
NS by passing a magnet near to the monitor. The mag-
net is worn on a bracelet. The times at which the mag-
netic event marker is registered are summed to produce
a 24 hour HF/NS frequency.
Health related quality of life General physical and men-
tal health are indexed using the General Health Survey
Short Form 36 (SF-36) [58], a widely used 36 item health
survey. Two physical and mental health summary scales are
constructed, with a possible range from 0 to 100, where
higher scores indicate better health [59]. Perceptions of
physical and emotional symptoms are measured using the
Women’s Health Questionnaire (WHQ) [49] which is stan-
dardised on samples of mid-aged women. The WHQ con-
tains 36 items, for example, “I feel more tired than usual”,
which are scored on 4-point scales. Nine subscales are
formed by counting the number of items scoring 2 or 3
and dividing by the number of items for each scale, result-
ing in scales from 0 to 1. The WHQ has been widely used
to evaluate interventions for menopausal symptoms [60].
Process measures
Beliefs about hot flushes and night sweats HF/NS
beliefs are measured using the Hot Flush Beliefs Scale
[15], a 27-item scale comprising three subscales includ-
ing social context, coping with hot flushes, and coping
with night sweats. An additional scale is included which
measures behavioural reactions to HF/NS, the Hot Flush
Behaviour Scale (HFBehS).
Perceived stress The Perceived Stress Scale [61] mea-
sures 10 items, for example “How often have you been
upset because of something that happened unexpect-
edly?”, on a scale from 0 (never) to 4 (very often). Items
are summed to form a 0-40 scale, where 0 is low stress
and 40 is high stress.
Somatic amplification Barsky, Grace and Klerman’s
[62] Somatic Amplification Scale is a 10 item scale mea-
suring a general tendency toward body focus, including
items such as “When someone else coughs, it makes me
cough too” (1 = not like me to 5 = very much like me).
The mean of the 10 items is calculated resulting in a
5-point scale where 5 is high somatic amplification.
Dispositional optimism The Revised Life Orientation
Test (LOT R [63]) measures dispositional optimism on
a8 - i t e ms c a l ei n c l u d i n g“In uncertain times, I usually
expect the best” (0 = strongly disagree to 4 = strongly
agree). A mean of all items is calculated, resulting in a
5-point scale where high scores indicate higher disposi-
tional optimism.
Treatment evaluation Participants randomised to the
group CBT arm are asked to rate the usefulness of the ses-
sions overall and of specific elements of the intervention;
use of the relaxation CD, attendance and completion of
homework are also being measured.
Adverse events
An adverse events protocol has been agreed by the
DMC and TSC, adapted for a non-medical trial using
the Medical Research Council/Department for Health
Joint Project Guideline notes on Pharmocovigilance
[64]. This excludes study outcomes, such as increases
in frequency or severity of HF/NS that occur as part of
normal fluctuations in menopause symptoms. Adverse
events are logged in the trial master file and reported to
the principle investigator and trial coordinator. In accor-
dance with the National Patient Safety Agency’s require-
ments for reporting of serious adverse events (SAE), any
adverse event deemed to be a related or unexpected
SAE will be reported to the principle investigator, the
sponsor and the DMC within 48 hours, and reported to
the Hospital Research Ethics Committee in accordance
with their procedures. Reoccurrence of breast cancer or
secondary cancer does not need to be reported in this
way, as it is an expected unrelated serious adverse event
(see appendix 3 of the Joint Guidelines [64]). An adverse
events report of these occurrences will be included in
the report to the DMC in accordance with the DMC
charter.
Power calculation
T h es a m p l es i z ei sc a l c u l a t e do nt h eH F R Sp r o b l e m
rating subscale [55], estimating a mean of 5 (SD = 2.4)
and a clinically relevant difference of 2 points [45] at
two weeks post-treatment. A total sample size of 76, 38
in each group, will have 90% power to detect a differ-
ence in mean HF/NS Problem Rating of 2, controlling
for baseline value, assuming a common standard devia-
tion of 2.4, a correlation between baseline and end of
treatment values of 0.4 (giving a correction factor of
0.84 [65]) and a 5% two-sided significance level. Due to
clustering of outcomes within therapy groups, the sam-
ple size has been adjusted by assuming an intra-class
correlation of 0.07 [66] and 8 participants per group giv-
ing a variance inflation factor of 1.49. Ninety six women
will be recruited in to the trial to allow for a 20% attri-
tion rate.
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An analysis plan has been agreed (i.e. prior to comple-
tion of data collection). A trial statistician, employed by
the Mental Health and Neurology Clinical Trials Unit at
King’s College London, carries out primary and second-
ary data analysis, and is blind to group allocation. Unless
indicated, scales are calculated according to published
scoring algorithms. All statistical tests are two sided
(level of significance = 0.05). The analyses are preformed
using the statistical software Stata version 11.0. An
intention to treat analysis of the primary outcome is
performed. Difference in problem rating between the
two intervention groups is tested using a linear mixed
model, utilising fixed and random effects. The regression
model compares the problem rating subscale of HFRS
between intervention groups, after allowing for the base-
line measurements to control for pre-treatment differ-
ences, stratification factors (age: 50 years or older versus
younger than 50 years), and clinically relevant covari-
ates. Greater precision of estimates is expected within
therapy groups. Therefore models are adjusted for the
therapy group; this variable is able to randomly vary
around the intercept (random effects). Secondary out-
comes at post-treatment are analysed similarly. Follow-
up data at 6 months is also explored through linear
mixed models utilising repeated measures analyses,
allowing simultaneous modelling of the two outcome
time points. Mediation of treatment effects by hot flush
beliefs and behaviours, mood, stress, quality of life and
frequency of HF/NS defined by skin conductance rises
will be explored using a two stage least squared method
in Stata [67]. Moderation by optimism and somatisation
is also tested using multiple-group modelling [68].
Discussion
This study is a randomised controlled trial of cognitive
behavioural therapy to treat hot flushes and/or night
sweats experienced by women who have completed
treatment for breast cancer. This non-medical treatment
aims to alleviate HF/NS symptoms in women who have
limited medical treatment options due to contraindica-
tions. It is a robustly designed trial, comparing six
sessions of Group CBT to usual care using both self-
reported and physiological outcome measures. The
primary outcome is change in HF/NS problem rating at
post-treatment: an average reduction in problem rating
of 2 points on the HFRS problem rating subscale is
needed for treatment efficacy to be considered clinically
significant. The study also tests the hypotheses that
Group CBT will reduce frequency of HF/NS, improve
mood, sleep, general wellbeing, and beliefs about HF/
NS. It is further hypothesised that these improvements
will be maintained at six months post-randomisation.
If this non-medical treatment is found to be successful
it could be delivered in primary or secondary care
settings by appropriately trained and supervised health
professionals.
Methodological considerations
The design has several strengths. The treatment has
been extensively developed and piloted for feasibility,
acceptability and preliminary outcomes. Preliminary
results found an average 2.5 point reduction in problem
rating (49% reduction) as well as a significant reduction
in self-reported frequency, and significant improvements
in sleep quality and quality of life were also reported
[47]. A treatment manual specifies the detail for each
session so that it is replicable, and checks are in place
to ensure adherence to protocol. Measures of treatment
efficacy are robust: as well as questionnaire-based esti-
mations of recent symptoms, the trial includes prospec-
tive monitoring of symptoms using self-report and
physiological measures. Very few trials of treatments for
HF/NS include both types of prospective monitoring,
and no trials of CBT for HF/NS have done so. The
s t u d ys a m p l ei sd r a w nf r o mas o c i a l l ya n dc u l t u r a l l y
diverse area of the UK; the uptake and adherence to the
treatment by women from different backgrounds will be
reported.
There are some limitations that should be considered.
Recruitment procedures are designed to reach all of the
symptomatic breast cancer patients who attend clinics
in the South East London Network (SELCRN) hospitals.
Clinic and research staff approach patients directly and
posters and leaflets are placed in waiting rooms so that
patients can opt in themselves. Nonetheless, the sample
might not be representative of symptomatic breast can-
cer patients in general and we cannot know how many
people were made aware of the trial through these
recruitment procedures.
The treatment is compared to a usual care group to
see whether it improves on current practice, but usual
care control groups have some drawbacks. Usual care
may vary between centres, although typically treatment
is minimal. Those receiving usual care may be more
likely to seek complimentary therapies if they are having
no other treatment. Complementary therapy use and
clinic treatments are monitored in the trial and may
have to be controlled for in analysis. If usual care is
minimal then it will be similar to a no-treatment control
group, and treatment effects might be due to the extra
attention rather than the treatment per se (i.e. any inter-
vention is better than nothing). Transitory changes and
biased reporting should be apparent by comparing self-
reported HF/NS with physiological measures and post-
treatment with follow up data. Early in the treatment
development phase it makes sense to compare with cur-
rent practice, especially as some improvement in usual
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get better in time. Should treatment effects be robust,
further research into the active treatment components
can be tested using attention control groups.
Conclusions
Breast cancer survivors who are experiencing proble-
matic HF/NS have few treatment options. Cognitive
behavioural therapy has resulted in some promising
reductions in HF/NS problem rating and frequency in
these women. This study is a randomised controlled
trial of Group CBT for HF/NS which also includes phy-
siological outcome measures. The trial tests for treat-
ment effects on HF/NS, sleep, mood, beliefs about HF/
NS and general wellbeing. This study represents an
important step in the development of a cost-effective
non-medical treatment for HF/NS designed to be imple-
mented on a wider scale by trained and supervised
health professions.
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